Related Experiment Video
Updated: May 14, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
[Extensive thromboembolism after cardioversion in a patient treated with dabigatran]
Torben Nicolai Buch1, Jakob Holm, Lars Kristian Munck
1Medicinsk Afdeling, Køge Sygehus, Lykkebækvej 1, 4600 Køge, Denmark. torbenbuch@gmail.com
Abstract:
A 65-year-old man, who had been treated with dabigatran for 66 days prior to electrical cardioversion, developed extensive intestinal, renal and cerebral thromboembolism five days after cardioversion. There is limited information available on the treatment of thromboembolism in patients being treated with dabigatran. Routine biochemical monitoring is not available. As is the case for vitamin K antagonists, anticoagulation with dabigatran is not without risks.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism III: Nursing Management
Dysrhythmias VI: Management of Dysrhythmias
